M&A
Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio
Mirati Therapeutics, long speculated to be a potential acquisition target in the world of Big Pharma, has now sealed a ...
Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution
Amgen has successfully concluded its monumental $27.8 billion acquisition of Horizon Therapeutics, triumphing over a legal challenge posed by the ...
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
AbbVie acquires mitochondria biotech to boost Parkinson’s research
AbbVie has made a significant move in the field of Parkinson’s disease by acquiring Mitokinin for an upfront payment of ...
Lilly Makes a Splash in Radiopharmaceuticals with $1.4B Acquisition of Point Biopharma
Eli Lilly is making a significant foray into the radiopharmaceutical cancer therapeutic sector with its acquisition of Point Biopharma Global ...
Intercept Pharmaceuticals, After 2 FDA Setbacks and Restructuring Efforts, Finds a Buyer in Italy’s Alfasigma
Intercept Pharmaceuticals has faced substantial challenges over the past three years, particularly after the FDA rejected its attempts to bring ...
Cerba HealthCare buys Cirion Biopharma to boost bioanalytical services
French clinical trial lab and diagnostics provider Cerba HealthCare has acquired Canadian CRO Cirion Biopharma in a move aimed at ...
Calidi Biotherapeutics goes public through SPAC deal to advance off-the-shelf cancer treatments
Calidi Biotherapeutics, a San Diego-based biotech, has chosen the special purpose acquisition company (SPAC) path to enter the public market, ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
Nestlé abandons $2 billion peanut allergy drug Palforzia after disappointing sales and safety issues
Nestlé has completed the sale of its peanut allergy drug, Palforzia, to the U.S.-based allergy specialist Stallergenes Greer for an ...
Otsuka acquires Mindset Pharma, a leader in psychedelic medicines for mental health
Japanese pharmaceutical giant Otsuka is embarking on a groundbreaking acquisition, setting its sights on Canada’s Mindset Pharma, a specialist in ...
Amgen seals the deal with Horizon for $28 billion, expanding its portfolio of rare disease drugs
After several months of legal battles, Amgen has finally received the green light for its $27.8 billion acquisition of Horizon ...
Serina Therapeutics merges with struggling AgeX Therapeutics to go public and advance its Parkinson’s drug
AgeX Therapeutics, a biotech that has been facing financial difficulties and stalled preclinical programs for years, has finally found a ...
Novo Nordisk acquires Embark Biotech for 15 million euros in obesity deal spree
Novo Nordisk has made another move to expand its obesity portfolio, acquiring Embark Biotech for 15 million euros ($16 million) ...
Abcam’s Harmonious Acquisition by Danaher Shaping the Future of Antibody Research
In the realm where science meets commerce, a symphony of strategy and innovation is playing out. Just two months since ...
Amgen challenges FTC’s bid to block $28B Horizon deal
Amid the ongoing legal battle with the Federal Trade Commission (FTC) over its $28 billion acquisition of Horizon Therapeutics, Amgen ...
LEO Pharma Set to Acquire Timber Pharmaceuticals
Timber Pharmaceuticals has exciting news to share—the company is set to be acquired by LEO US Holding, Inc., a wholly-owned ...
Biogen Outbids Competitor in $7.3 Billion Reata Pharmaceuticals Acquisition Duel
In a surprising turn of events, Biogen’s acquisition of Reata Pharmaceuticals for $7.3 billion raised eyebrows among industry observers last ...
Novartis Acquires Chinook Therapeutics for USD 3.5 Billion to Boost its Renal Portfolio
Novartis, a global pharmaceutical giant, has finalized its deal to buy Chinook Therapeutics, a biotech company that specializes in developing ...
Babylon shutters its US operations after a failed rescue merger deal
Babylon Health’s efforts to secure funding and stabilize its operations have been thwarted due to the collapse of a planned ...
eureKING purchases SCTbio to further its bio manufacturing initiative
eureKING, a special purpose acquisition company (SPAC) established last year with a substantial investment of over €150 million, has finalized ...
PacBio to Acquire Apton Biosystems for Next-Gen Short-Read Sequencer Development
Source – PacBio Gene sequencing specialist PacBio has signed an agreement to acquire Apton Biosystems, a move that will enhance ...
How EQRx’s Cheap Drugs Strategy Led to Revolution Deal
Source – Revolution Medicines EQRx, which made a bold claim to disrupt the pharmaceutical pricing system in 2020, has now ...
Even after buying Prometheus for $10.8 billion, Merck is still looking for M&A opportunities
Earlier this year, Merck’s acquisition of Prometheus Biosciences for $10.8 billion provided the New Jersey company with a much-needed diversification ...
Biogen Buys Reata and Skyclarys for $7.3B, Cuts Jobs
During a quarterly earnings call, Biogen CEO Chris Viehbacher unexpectedly mentioned that the company had around $7.3 billion in cash. ...
In a $466 million agreement, Sosei acquires the Japan and Korea subsidiaries of Idorsia
Source – Sosei Heptares Japan’s Sosei Group has successfully transformed into a commercial-stage pharmaceutical company by acquiring the rights to ...
Enhanced Merger Standards by FTC and DOJ Signal Heightened Scrutiny of M&A Transactions
As the Federal Trade Commission (FTC) closely examines two significant biopharma mergers, both the FTC and the Department of Justice ...
Healthcare bucks the trend with a 2-year M&A high
On July 4, Data from LSEG Deals Intelligence revealed that the healthcare sector experienced a notable 35% increase in deals, ...
